BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $TAK readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06812078-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TAK-360 readout (P2) · Takeda $TAK
DESCRIPTION:A Study of TAK-360 in Adults With Idiopathic Hypersomnia\n\nPri
 mary completion date: 2026-11-30 (estimated)\nOriginally planned: 2026-02-
 19 (+9.3 months)\nPhase 2 · Neuro · Idiopathic Hypersomnia\nEnrollment: 
 96 · Sites: 29\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tri
 alsonar.netlify.app/radar.html?nct=NCT06812078\nhttps://clinicaltrials.gov
 /study/NCT06812078
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06812078
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952699-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TAK-360 readout (P2) · Takeda $TAK
DESCRIPTION:A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy 
 (NT2)\n\nPrimary completion date: 2026-11-30 (estimated)\nOriginally plann
 ed: 2026-03-23 (+8.3 months)\nPhase 2 · Other · Narcolepsy Type 2\nEnrol
 lment: 88 · Sites: 52\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://trialsonar.netlify.app/radar.html?nct=NCT06952699\nhttps://clinicaltri
 als.gov/study/NCT06952699
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06952699
CATEGORIES:Other,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363720-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:TAK-861 readout (P3) · Takeda $TAK
DESCRIPTION:A Trial of TAK-861 for the Treatment of Narcolepsy With Cataple
 xy\n\nPrimary completion date: 2026-12-17 (estimated)\nOriginally planned:
  2026-10-02 (+2.5 months)\nPhase 3 · Neuro · Narcolepsy Type 1 (NT1)\, N
 arcolepsy With Cataplexy\nEnrollment: 98 · Sites: 25\n\nPrimary completio
 n = last participant's primary-endpoint data collected\; topline results u
 sually follow weeks to months later. Sponsor-reported\, often an estimate.
  Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=N
 CT07363720\nhttps://clinicaltrials.gov/study/NCT07363720
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07363720
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319353-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:Maribavir readout (P3) · Takeda $TAK
DESCRIPTION:A Study to Evaluate the Safety and Tolerability\, Pharmacokinet
 ics\, and Antiviral Activity of Maribavir for the Treatment of Cytomegalov
 irus (CMV) Infection in Children and Adolesc…\n\nPrimary completion date
 : 2027-01-18 (estimated)\nPhase 3 · Infectious · Cytomegalovirus (CMV)\n
 Enrollment: 80 · Sites: 53\n\nPrimary completion = last participant's pri
 mary-endpoint data collected\; topline results usually follow weeks to mon
 ths later. Sponsor-reported\, often an estimate. Not investment advice.\n\
 nhttps://trialsonar.netlify.app/radar.html?nct=NCT05319353\nhttps://clinic
 altrials.gov/study/NCT05319353
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05319353
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244263-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Zasocitinib (Dose A) readout (P2) · Takeda $TAK
DESCRIPTION:A Study of Zasocitinib in Adults With Hidradenitis Suppurativa\
 n\nPrimary completion date: 2027-02-05 (estimated)\nOriginally planned: 20
 28-02-22 (-12.5 months)\nPhase 2 · Infectious · Hidradenitis Suppurativa
 \nEnrollment: 91 · Sites: 45\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07244263\nhttps://clin
 icaltrials.gov/study/NCT07244263
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07244263
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973304-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Teduglutide readout (P3) · Takeda $TAK
DESCRIPTION:A Study of Teduglutide in Chinese Adults With Short Bowel Syndr
 ome\n\nPrimary completion date: 2027-02-10 (estimated)\nPhase 3 · GI·Ren
 al·Heme · Short Bowel Syndrome\nEnrollment: 13 · Sites: 4\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.htm
 l?nct=NCT06973304\nhttps://clinicaltrials.gov/study/NCT06973304
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06973304
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06233461-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:TAK-279 readout (P2) · Takeda $TAK
DESCRIPTION:A Study on the Safety of TAK-279 and Whether it Can Reduce Infl
 ammation in the Bowel of Participants With Moderately to Severely Active C
 rohn's Disease\n\nPrimary completion date: 2027-02-17 (estimated)\nOrigina
 lly planned: 2026-09-18 (+5.0 months)\nPhase 2 · GI·Renal·Heme · Crohn
 's Disease\nEnrollment: 268 · Sites: 201\n\nPrimary completion = last par
 ticipant's primary-endpoint data collected\; topline results usually follo
 w weeks to months later. Sponsor-reported\, often an estimate. Not investm
 ent advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06233461\n
 https://clinicaltrials.gov/study/NCT06233461
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06233461
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683003-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:TAK-755 readout (P3) · Takeda $TAK
DESCRIPTION:A Study of TAK-755 in Participants With Congenital Thrombotic T
 hrombocytopenic Purpura\n\nPrimary completion date: 2027-03-16 (estimated)
 \nOriginally planned: 2026-08-27 (+6.6 months)\nPhase 3 · Cardio-Met · T
 hrombotic Thrombocytopenic Purpura (TTP)\nEnrollment: 77 · Sites: 27\n\nP
 rimary completion = last participant's primary-endpoint data collected\; t
 opline results usually follow weeks to months later. Sponsor-reported\, of
 ten an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/
 radar.html?nct=NCT04683003\nhttps://clinicaltrials.gov/study/NCT04683003
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04683003
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108283-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Zasocitinib readout (P2) · Takeda $TAK
DESCRIPTION:A Study of Zasocitinib in Adults With Nonsegmental Vitiligo\n\n
 Primary completion date: 2027-03-26 (estimated)\nOriginally planned: 2027-
 10-12 (-6.6 months)\nPhase 2 · Immuno · Nonsegmental Vitiligo\nEnrollmen
 t: 207 · Sites: 67\n\nPrimary completion = last participant's primary-end
 point data collected\; topline results usually follow weeks to months late
 r. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:/
 /trialsonar.netlify.app/radar.html?nct=NCT07108283\nhttps://clinicaltrials
 .gov/study/NCT07108283
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07108283
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06579755-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270414
DTEND;VALUE=DATE:20270415
SUMMARY:TDV readout (P3) · Takeda $TAK
DESCRIPTION:A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 t
 o 60 and >60 to 79 Years)\n\nPrimary completion date: 2027-04-14 (estimate
 d)\nOriginally planned: 2026-03-14 (+13.0 months)\nPhase 3 · Infectious 
 · Dengue Fever\nEnrollment: 800 · Sites: 7\n\nPrimary completion = last 
 participant's primary-endpoint data collected\; topline results usually fo
 llow weeks to months later. Sponsor-reported\, often an estimate. Not inve
 stment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT0657975
 5\nhttps://clinicaltrials.gov/study/NCT06579755
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06579755
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671483-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:Zasocitinib readout (P3) · Takeda $TAK
DESCRIPTION:A Study of Zasocitinib in Adults With Psoriatic Arthritis Who H
 ave Not Taken Biologic Medicines\n\nPrimary completion date: 2027-05-18 (e
 stimated)\nPhase 3 · Immuno · Psoriatic Arthritis\nEnrollment: 1583 · S
 ites: 184\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://trialsona
 r.netlify.app/radar.html?nct=NCT06671483\nhttps://clinicaltrials.gov/study
 /NCT06671483
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06671483
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671496-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:Zasocitinib readout (P3) · Takeda $TAK
DESCRIPTION:A Study of Zasocitinib in Adults With Psoriatic Arthritis Who H
 ave or Have Not Been Treated With Biologic Medicines\n\nPrimary completion
  date: 2027-05-18 (estimated)\nPhase 3 · Immuno · Psoriatic Arthritis\nE
 nrollment: 601 · Sites: 120\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://trialsonar.netlify.app/radar.html?nct=NCT06671496\nhttps://clini
 caltrials.gov/study/NCT06671496
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06671496
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752108-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Zasocitinib readout (P3) · Takeda $TAK
DESCRIPTION:A Study of Zasocitinib in Adults With Non-pustular Palmoplantar
  Psoriasis\n\nPrimary completion date: 2027-05-30 (estimated)\nPhase 3 · 
 Immuno · Palmoplantar Psoriasis\nEnrollment: 40 · Sites: 0\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.htm
 l?nct=NCT07752108\nhttps://clinicaltrials.gov/study/NCT07752108
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07752108
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227910-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:VICTRIVA readout (P3) · Takeda $TAK
DESCRIPTION:A Study of Vedolizumab With and Without Upadacitinib in Adults 
 With Crohn's Disease\n\nPrimary completion date: 2027-06-08 (estimated)\nP
 hase 3 · GI·Renal·Heme · Crohn's Disease\nEnrollment: 396 · Sites: 13
 8\n\nPrimary completion = last participant's primary-endpoint data collect
 ed\; topline results usually follow weeks to months later. Sponsor-reporte
 d\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netlif
 y.app/radar.html?nct=NCT06227910\nhttps://clinicaltrials.gov/study/NCT0622
 7910
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06227910
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04779320-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Vedolizumab IV readout (P3) · Takeda $TAK
DESCRIPTION:A Study of Vedolizumab in Children and Teenagers With Moderate 
 to Severe Crohn's Disease (CD)\n\nPrimary completion date: 2027-09-13 (est
 imated)\nOriginally planned: 2024-11-30 (+33.4 months)\nPhase 3 · GI·Ren
 al·Heme · Crohn's Disease (CD)\nEnrollment: 120 · Sites: 96\n\nPrimary 
 completion = last participant's primary-endpoint data collected\; topline 
 results usually follow weeks to months later. Sponsor-reported\, often an 
 estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.h
 tml?nct=NCT04779320\nhttps://clinicaltrials.gov/study/NCT04779320
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04779320
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03221036-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Vedolizumab IV readout (P3) · Takeda $TAK
DESCRIPTION:Efficacy and Safety of Vedolizumab IV in Chinese Participants W
 ith Ulcerative Colitis\n\nPrimary completion date: 2027-09-24 (estimated)\
 nOriginally planned: 2020-10-22 (+83.0 months)\nPhase 3 · GI·Renal·Heme
  · Moderately to Severely Active Ulcerative Colitis\nEnrollment: 392 · S
 ites: 36\n\nPrimary completion = last participant's primary-endpoint data 
 collected\; topline results usually follow weeks to months later. Sponsor-
 reported\, often an estimate. Not investment advice.\n\nhttps://trialsonar
 .netlify.app/radar.html?nct=NCT03221036\nhttps://clinicaltrials.gov/study/
 NCT03221036
URL:https://trialsonar.netlify.app/radar.html?nct=NCT03221036
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648030-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Rusfertide readout (P2) · Takeda $TAK
DESCRIPTION:A Study of Rusfertide in Japanese Adults With Polycythemia Vera
 \n\nPrimary completion date: 2027-10-28 (estimated)\nPhase 2 · Oncology 
 · Polycythemia Vera\nEnrollment: 9 · Sites: 9\n\nPrimary completion = la
 st participant's primary-endpoint data collected\; topline results usually
  follow weeks to months later. Sponsor-reported\, often an estimate. Not i
 nvestment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT0764
 8030\nhttps://clinicaltrials.gov/study/NCT07648030
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07648030
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
